We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Molecular Diagnostic Test for Lung Cancer Is Highly Accurate

By Biotechdaily staff writers
Posted on 09 Oct 2007
A study found that a molecular diagnostic test for lung cancer demonstrated high levels of accuracy.

A standardized reverse transcription polymerase chain reaction (StaRT-PCR) platform technology was used for measuring messenger RNA (mRNA) transcripts levels of 15 genes that could serve to predict lung cancer. More...
The test for these genes, in normal cells sampled via bronchoscopy, identified those individuals genetically at risk for lung cancer. In a study of 49 subjects, the test was able to correctly identify the individuals with cancer 96% of the time.

James C. Willey, M.D., founder and chief science and medical consultant to the company Gene Express (Toledo, OH, USA), and colleagues from the University of Toledo (OH, USA) measured transcript abundance (TA) of 15 genes that encode protective antioxidant and DNA repair proteins in lung airway cells taken from 25 people with lung cancer and 24 people without the disease. Their previous research allowed them to determine the threshold levels of TA for each gene--the point at which the amount of mRNA transcripts would indicate a tendency toward cancer. In this study, they used the threshold levels as a basis to assign a value of one or zero to each of the targeted genes for an individual subject, with "zero” indicating normal TA.

If the sum total of a subject's target genes was greater than or equal to seven, the genes could collectively serve as a biomarker for lung cancer. The results yielded one false negative and seven false positives among the 49 individuals assessed. According to Dr. Willey, a positive result in a subject without lung cancer may not actually be a false positive, but rather could mean that the person is at an increased risk for lung cancer, which might arise later.

"Overall, the study showed a high degree of accuracy for picking out lung cancer patients,” said Dr. Willey. CEO of Gene Express, Gerald Vardzel added, "We are excited about these results, as they demonstrate the value of our platform technology in the development of molecular diagnostics and the movement towards personalized medicine.”

The study was presented at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development in September 2007, which was held in Atlanta, GA (USA).


Related Links:
Gene Express
University of Toledo

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Overview of a rapid diagnostic workflow for fungal bloodstream infections (Photo courtesy of Professor Hiroki Takahashi and IMO, Chiba University, Japan)

Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.